Novanta Inc. develops and produces precision photonics, vision, and motion-control components and subsystems for healthcare and advanced industrial OEMs. The name itself highlights its emphasis on innovation and technical accuracy. I follow the company because it holds a unique spot in the supply chain, delivering the specialized parts that power medical devices, lab instruments, laser systems, and factory automation equipment from leading global manufacturers.
Novanta dates back to 1968 and operated for years as GSI Group before the 2016 rebrand. Headquartered in Bedford, Massachusetts, it runs design and manufacturing sites across North America, Europe, and Asia with a team of about 3,000 people. The model focuses on mission-critical, engineered components built into customers’ products. These solutions often have long life cycles and strict performance standards, which helps create switching costs and lasting relationships. Sales occur through direct teams and distributors, and growth has come from a steady acquisition approach that brings in complementary technologies.
Results break down into two segments. The Automation Enabling Technologies segment covers laser beam steering, laser sources such as CO2 and ultrafast lasers, encoders, precision motors, motion control, robotic tooling, and air-bearing spindles. These support industrial processing, robotics, metrology, and certain medical laser uses. The Medical Solutions segment includes insufflators, endoscopic pumps, imaging and RFID solutions, advanced motion control, light engines, and integrated operating-room systems for minimally invasive procedures. The segments contribute fairly evenly to revenue, reflecting a balanced medical and industrial exposure. The company maintains a portfolio of brands including Cambridge Technology, Synrad, Laser Quantum, ARGES, Celera Motion, ATI Industrial Automation, JADAK, and Westwind.
Novanta draws interest because it aligns with long-term trends in robotic surgery, lab automation, medical imaging, DNA sequencing, and precision manufacturing. As customers adopt more advanced equipment, demand for the components it supplies tends to rise in tandem. Competitive strengths include deep engineering know-how, a solid patent portfolio, and long design ties with major OEMs. Components are often customized and validated over years, which makes them hard to displace. The company has also shown consistent success with acquisitions that expand its offerings. A large share of sales comes from outside the United States. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Novanta faces typical risks for a precision supplier. Demand can fluctuate with customers’ capital-spending cycles, which are sensitive to broader economic conditions. Customer concentration matters, as a handful of large OEMs can account for a notable portion of revenue, so losing one could have a sizable effect. Acquisitions bring integration and goodwill considerations, and related costs can affect short-term results. The company competes in fast-moving markets that require ongoing innovation, and its international operations expose it to currency swings, trade shifts, and regional volatility. Without a dividend, returns rely mainly on share-price growth.
When evaluating names like NOVT, I often turn to Tickeron’s AI Screener to compare technical indicators, fundamentals, and industry patterns. It helps surface ideas that align with specific strategies and keeps the research process efficient without replacing my own judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NOVT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 05, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 55 instances where the indicator turned negative. In 42 of the 55 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 76%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NOVT as a result. In 69 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
NOVT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NOVT crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 68%.
The 50-day moving average for NOVT moved below the 200-day moving average on November 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NOVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +10.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where NOVT advanced for three days, in 195 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
NOVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. NOVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.162) is normal, around the industry mean (1.448). P/E Ratio (85.000) is within average values for comparable stocks, (5.350). NOVT's Projected Growth (PEG Ratio) (23.270) is slightly higher than the industry average of (5.470). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (5.043) is also within normal values, averaging (32.028).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of manufactures and sells precision photonic and motion control components
Industry ElectronicEquipmentInstruments